Clinical Research Staff/Coordinator: Roles and Responsibilities

Coordinators advocate for adequate budgetary resources and ensure financial stewardship, particularly regarding billing for research-related costs and standard of care. This includes understanding Medicare coverage for qualified clinical trials. Drug accountability is another key responsibility, enforcing strict control over investigational products, meticulous record-keeping, proper labeling, and adherence to storage conditions and destruction policies.

The speaker introduces the role of a research coordinator, emphasizing its evolution alongside new drug and device development. Key areas of responsibility are highlighted, including ethics, protocol compliance, regulatory affairs, informed consent, data management, and finances. The importance of a well-rounded research team is stressed, with coordinators often acting as central figures outside of the principal investigator.

The principal investigator (PI) holds overall accountability for scientific integrity, patient medical management, and ensuring personnel training. While FDA guidelines primarily focus on investigator responsibilities, many tasks are delegated to research staff. The crucial aspect is proper delegation and supervision, ensuring that all delegated tasks align with staff qualifications and licensure.

Before a trial begins, the research coordinator is responsible for confirming feasibility, including institutional capabilities, patient population, and regulatory approvals. This involves obtaining IRB approval, ensuring all staff have necessary training and certifications, and managing all required documentation like investigator signatures and clinical trial registrations.

The research coordinator plays a critical role in facilitating the informed consent process. This includes ensuring compliance with institutional policies, obtaining initial and ongoing consent, and effectively communicating trial details to participants. It's emphasized that consent is an ongoing process, requiring continuous education and reinforcement, and the coordinator ensures all forms and discussions adhere to regulatory standards.

Coordinators implement recruitment plans, identify eligible individuals, and overcome barriers to participation. This involves collaboration with referring physicians, understanding limited chart review protocols for eligibility screening, and adhering to strict rules regarding recruitment materials and advertising, avoiding any coercive language or promises.

Effective data management is crucial, involving collaboration with the investigator for eligibility confirmation, scheduling events, and ensuring accurate and timely data collection. Source documentation, which includes original records like pathology reports and physician notes, must be meticulously maintained. The importance of clear, consistent terminology across databases and adherence to record retention policies (typically 2-15 years depending on regulations) is highlighted.

Research coordinators are delegated the responsibility of collecting and reporting adverse events (AEs). This involves accurate terminology, determining attribution (relating the event to the study drug/procedure), and assessing expectedness. Reporting requirements vary by IRB, sponsor, and FDA, and serious AEs and unanticipated problems (like data breaches or protocol violations) must be promptly reported.

Sponsors routinely monitor clinical trials to ensure compliance and data integrity. These monitoring visits vary in frequency and intensity, with risk-based monitoring becoming more common. FDA inspections are also a possibility, either routine or for-cause, often triggered by concerns about patient safety or data integrity. Coordinators must be prepared for these oversight activities and have corrective action plans in place.

The presentation concludes with a review of key responsibilities, distinguishing between regular duties of a site coordinator and tasks that require delegation from the investigator. It emphasizes the importance of clear communication with referring physicians and proper documentation across all aspects of the clinical trial process.